two new protease inhibitors for hepatitis C, Incivek (telaprevir) and Victrelis (boceprevir)

August 2011

You'll see two new protease inhibitors for hepatitis C, Incivek (telaprevir) and Victrelis (boceprevir).

That's right...protease inhibitors for hep C.

These are "game changers." They lead to much higher cure rates and shortened treatment duration. They're ADDED to pegylated interferon and ribavirin for genotype 1 hep C.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Antiplatelets Brilinta, a new antiplatelet drug
Hepatitis C two new protease inhibitors for hepatitis C, Incivek (telaprevir) and Victrelis (boceprevir)
Anticoagulants new ORAL anticoagulant called Xarelto (zuh-REL-toe)
Statins if statins increase the risk of diabetes
Men's Health Staxyn (STAX-in), a new orally disintegrating tablet version of vardenafil (Levitra)
Men's Health new warnings about the risk of prostate cancer with finasteride (Proscar, etc) or dutasteride (Avodart, etc)
Respiratory & Allergy which long-acting bronchodilator to use first-line for COPD
Pneumonia You wouldn't think IV dexamethasone would be a good idea for a patient hospitalized with community-acquired pneumonia (CAP)
Vitamins & Minerals Is it ever necessary to give vitamin B12 by injection
Psychiatry New VA guidelines for post-traumatic stress disorder
Sunscreens New rules for sunscreens
Smoking Cessation new warnings about Chantix and an increased risk of cardiac events in patients with heart disease

two new protease inhibitors for hepatitis C, Incivek (telaprevir) and Victrelis (boceprevir)

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents